Publikationen in Zusammenarbeit mit Forschern von University of Nebraska Medical Center (25)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide

    The Lancet Oncology, Vol. 24, Núm. 12, pp. e472-e518

2022

  1. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Leukemia, Vol. 35, Núm. 1, pp. 18-30

  3. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 27, Núm. 10, pp. 807-816

  4. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

2020

  1. Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers

    Blood, Vol. 136, Núm. 11, pp. 1303-1316

2018

  1. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials

    JAMA Ophthalmology, Vol. 136, Núm. 6, pp. 666-677

  2. Reprogramming human T cell function and specificity with non-viral genome targeting

    Nature, Vol. 559, Núm. 7714, pp. 405-409

2017

  1. Global Forum of Cancer Surgeons: Declaration of Intent

    Annals of Surgical Oncology

2014

  1. Classification of current anticancer immunotherapies

    Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508

  2. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma

    Nature Communications, Vol. 5

2012

  1. Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: A phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

    British Journal of Cancer, Vol. 107, Núm. 5, pp. 808-813

1997

  1. Human leukocyte antigen class II associations in patients with idiopathic dilated cardiomyopathy

    Journal of Cardiac Failure, Vol. 3, Núm. 2, pp. 97-103

1996

  1. Clonality analysis of B-lymphoid proliferations using the polymerase chain reaction

    Cancer, Vol. 77, Núm. 7, pp. 1349-1355

  2. High-resolution analysis of immunoglobulin heavy-chain gene rearrangements using denaturing gradient gel electrophoresis

    Diagnostic Molecular Pathology, Vol. 5, Núm. 3, pp. 159-165